[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasopharyngeal-carcinoma-xerostomiaradiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasopharyngeal-carcinoma-xerostomiaradiotherapy":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,37],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":25,"whyStopped":4,"lastUpdateSubmitDate":26,"lastUpdatePostDateStruct":27,"startDateStruct":30,"completionDateStruct":32,"leadSponsor":34,"locationsCount":4},"100573830","monitoring-salivary-gland-injury-in-nasopharyngeal-carcinoma-patients-after-radiotherapy-using-multi-modal-radiomics-100573830",false,"NCT06751381","Monitoring Salivary Gland Injury in Nasopharyngeal Carcinoma Patients After Radiotherapy Using Multi-Modal Radiomics","A Prospective Study on Monitoring Salivary Gland Injury in Nasopharyngeal Carcinoma Patients After Radiotherapy Using Multi-Modal Radiomics","Inclusion Criteria:\n\n1. Histologically or cytologically confirmed diagnosis of nasopharyngeal carcinoma.\n2. Scheduled to undergo radiotherapy as part of standard treatment.\n3. Aged 18 years or older.\n4. No contraindications to MRI scans (e.g., no implanted metallic devices).\n5. Written informed consent has been provided.\n\nExclusion Criteria:\n\n1. Contraindications to MRI, such as metallic implants or claustrophobia.\n2. Severe comorbid conditions, including significant renal or hepatic dysfunction.\n3. Concurrent participation in another interventional clinical trial.\n4. Pregnant or breastfeeding.\n5. Any condition that may impair compliance with study procedures.","ALL","18 Years",{"count":19,"type":20},45,"ESTIMATED","OBSERVATIONAL","This prospective observational study aims to evaluate the role of intravoxel incoherent motion (IVIM) imaging and magnetic resonance fingerprinting (MRF) techniques in monitoring salivary gland injury in nasopharyngeal carcinoma (NPC) patients undergoing radiotherapy. The study will recruit patients diagnosed with NPC who are receiving standard radiotherapy, and quantitative imaging data will be collected using IVIM and MRF techniques at multiple time points, including pre-treatment, during radiotherapy, and post-treatment. The primary objective is to analyze changes in salivary gland structure and function and to identify early imaging biomarkers indicative of radiation-induced injury. The findings are expected to provide new insights into the dynamic progression of salivary gland damage, establish predictive models for the risk of xerostomia, and guide the development of personalized therapeutic strategies to mitigate long-term complications.",[24],"Nasopharyngeal Carcinoma ,Xerostomia,Radiotherapy","NOT_YET_RECRUITING","2025-01-12",{"date":28,"type":29},"2025-01-14","ACTUAL",{"date":31,"type":20},"2025-01-20",{"date":33,"type":20},"2026-12-06",{"name":35,"class":36},"Hainan Medical College","OTHER",{"id":38,"slug":39,"hasResults":11,"nctId":40,"briefTitle":41,"officialTitle":42,"acronym":4,"eligibilityCriteria":43,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":44,"enrollmentInfo":45,"targetDuration":4,"studyType":47,"phases":48,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":62},"100537797","xerostomia-optimised-imrt-versus-standard-imrt-in-npc-100537797","NCT06282497","Xerostomia-optimised IMRT Versus Standard IMRT in NPC","Xerostomia-optimised Intensity-modulated Radiotherapy Versus Standard Intensity-modulated Radiotherapy in Nasopharyngeal Carcinoma Patients:a Multicenter Non-inferior Randomized Controlled Phase III Clinical Trial","Inclusion Criteria:\n\n* Newly histologic diagnosis of nasopharyngeal non-keratinizing carcinoma (WHO II\u002FIII);\n* All genders, range from 18-70 years old;\n* ECOG score 0-1;\n* Clinical stage I-IVa (AJCC\u002FUICC 8th);\n* Not received radiotherapy, chemotherapy and other anti-tumor treatment (including immunotherapy);\n* No contraindications to chemotherapy or radiotherapy;\n* Adequate organ function: white blood cell count ≥ 4×109\u002FL, neutrophile granulocyte count ≥ 1.5×109\u002FL, hemoglobin ≥ 90g\u002FL, platelet count ≥ 100×109\u002FL; alanine aminotransferase or aspartate aminotransferase \\\u003C 2.5×upper limit of normal; blood urea nitrogen or creatinine ≤ 1.5×upper limit of normal or endogenous creatinine clearance ≥ 60ml\u002Fmin (Cockcroft-Gault formula);\n* Sign the consent form.\n\nExclusion Criteria:\n\n* Level II involvement with extracapsular extension (ECE), and\u002For had a maximum nodal axial diameter (MAD) of greater than 3cm in level II ;\n\n  -≥4 nodal regions of ipsilateral neck involvement;\n* Radiologically suspicious or confirmed involvement in level II area between skull base and the lateral process of C1;\n* Parotid lymph node and\u002For parotid gland involvement;\n* History of parotid disease or surgery;\n* Previous malignancy or other concomitant malignant disease;\n* Pregnancy or lactation.","70 Years",{"count":46,"type":20},524,"INTERVENTIONAL",[49],"NA","This is a multi-center, non-inferiority, open-label, randomized controlled phase III clinical trial in primary diagnosed nasopharyngeal carcinoma (NPC) patients without distant metastasis. This study aims to compare the regional control, survival outcomes, radiation-related toxicities, and quality of life (QoL) of xerostomia-optimized intensity-modulated radiotherapy versus standard intensity-modulated radiotherapy in NPC patients",[24],"RECRUITING","2024-04-28",{"date":55,"type":29},"2024-05-01",{"date":57,"type":29},"2023-10-23",{"date":59,"type":20},"2029-10-23",{"name":61,"class":36},"Zhongshan People's Hospital, Guangdong, China",1]